Xention Ltd   Report issue

For profit Phase 1 Phase 2
Founded: Pampisford United States (2002)
Status: Defunct (2016)

Organization Overview

First Clinical Trial
2011
NCT02390258
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2015

Timeline

NOW
  • Now

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Atrial Fibrillation (Phase 1)

Cough (Phase 2)

Dyslipidemias (Phase 2)

Lung Diseases (Phase 2)

Lung Diseases, Obstructive (Phase 2)

Pulmonary Disease, Chronic Obstructive (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 9
  • # of Trial APIs: 8